Sponsors (28)
The bill boosts antimicrobial R&D, availability, stewardship, and preparedness—benefiting patients, hospitals, researchers, and national security—but raises federal costs, potential drug-price and allocation concerns, and administrative burdens for health systems.
Patients with chronic conditions and other patients will have greater access to effective antimicrobials because the bill promotes R&D and market pathways for lifesaving drugs.
Hospitals, health systems, and healthcare workers will gain new tools, programs, and stewardship support to better prevent and treat drug-resistant infections, improving patient safety and reducing antimicrobial resistance.
Scientists and researchers will receive increased federal support for antimicrobial R&D, accelerating development of new antibiotics, diagnostics, and related therapies.
Taxpayers could face increased federal spending to support expanded R&D, procurement, and programs without clear offsets, raising the deficit or requiring other budget trade-offs.
Clinicians, hospitals, and state public-health agencies may face new regulatory complexity and administrative burdens from added programs, procurement rules, or stewardship requirements.
Prioritizing antimicrobial supply for military readiness could create allocation and fairness questions between military and civilian patients during shortages.
Based on analysis of 3 sections of legislative text.
Adds a new Title III Public Health Service authority to promote development, access, stewardship, and preparedness for antimicrobials (specific program text not included).
Official title: To amend the Public Health Service Act to establish a program to develop innovative antimicrobial drugs targeting the most challenging pathogens and most threatening infections, and for other purposes.
Introduced February 4, 2026 by Buddy Carter · Last progress February 4, 2026
Creates a new Public Health Service authority to promote development, availability, and appropriate use of lifesaving antimicrobials. The law is intended to spur research and market access for new antibiotics and related products, strengthen medical standards and stewardship, and support national and military preparedness against resistant infections. The bill adds a new "Developing antimicrobial innovations" provision to Title III of the Public Health Service Act but the text of that new program is not included in the excerpt, so specific program details, funding levels, and deadlines are not available in the provided summary.